# Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

> **NCT06406634** · PHASE2 · RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06406634
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2026-04-20
- **Final completion:** 2027-04-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06406634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06406634, "Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06406634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*